Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 27 min ago
Peer-reviewedCC BYCureus

Community Experience of COVID-19 Hospitalizations.

  1. 1Graduate Medical Education, Community Memorial Healthcare, Ventura, USA.
  2. 2Pacific Inpatient Physicians, Community Memorial Hospital, Ventura, USA.

Abstract

Background Every American was affected by the COVID-19 pandemic. The novelty and virulence spurred the rapid evolution of treatment strategies. While large multicenter studies established key mortality risk factors and treatment efficacy, community hospital experiences are underrepresented. Methods This retrospective study examines clinical characteristics, mortality predictors, and outcome trends among 1,949 adults hospitalized with COVID-19 at a Southern California community hospital from January 31, 2020, through May 11, 2023. Results Overall mortality was 7.6%, and the mean length of stay was 9.2 days. Older age was independently associated with increased mortality, with the odds of death nearly doubling for every decade of life (adjusted odds ratio (aOR) 1.98, 95% CI 1.65-2.39, P < 0.001). Univariable laboratory predictors of inpatient mortality, and log transformation of D-dimer, demonstrated that D-dimer was the best predictor of inpatient mortality. Septic shock was associated with a twofold increase in mortality (aOR 2.26, 95% CI 1.11-4.63, P = 0.025). Respiratory failure requiring a mechanical ventilator is a marker for disease severity and was the strongest predictor of mortality in this cohort. Mechanical ventilation was associated with a 10-fold increase in the odds of death (aOR 10.07, 95% CI 6.18-16.38, P < 0.001). Multivariable analysis comparing mortality and pharmaceutical treatments identified that receipt of systemic corticosteroids was associated with higher odds of in-hospital mortality (aOR 6.70; 95% CI 4.00-11.22; P < 0.001). Receipt of tocilizumab was also associated with higher mortality (aOR 3.87; 95% CI 2.06-7.26; P < 0.001). Time-lapse analysis of the interval between admission and mortality demonstrated a 23% reduction in the odds of death per successive year (aOR 0.77 per year, 95% CI 0.62-0.96, P = 0.018). Conclusion Mortality decreased nearly one-fourth each year. D-dimer was the best laboratory predictor of death. Older age, septic shock, and ventilator need were associated with increased risk of inpatient mortality. Receipt of systemic steroids and tocilizumab was associated with higher mortality. These are not causal treatment effects, as medication receipt at that time was related to disease severity. These community hospital findings complement larger studies and reinforce the importance of early risk stratification and evidence-based treatments.

Related

  1. Symptom clusters in Long COVID in the UK: prospective community-based cohort study using unsupervised machine learning
    Jasmine Aherne, Ines Henriques-Cadby, Thomas House
    arXivPreprintarXiv licenceFull textStatisticsarXiv
  2. Pathogen-specific ripple effects of COVID-19 nonpharmaceutical interventions in reshaping endemic disease dynamics
    Daipeng Chen, Seyed M. Moghadas, Gergely Röst
    Communications MedicinePeer-reviewedCC BY-NC-ND 4.0Full textGeneral mathematicsCrossref
  3. A COVID-19 transmission model with optimal control integrating BERT with LHS and least-squares fitting for real-world consistency
    Yinghui Chen, Chairat Modnak
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral mathematicsCrossref
  4. A partial post-review by a peer of the peer-reviewed article [1] "Modeling COVID-19 transmission: effects of age structure and vaccination, published in 2025 in the Springer Nature journal \it{\bf Scientific Reports}
    Fatiha Alabau-Boussouira
    HALPreprintPublisher termsFull textGeneral mathematicsHAL
  5. Le retour d'information aux entreprises enquêtées : l'expérience du SESSI
    Jean-Paul François
    Courrier des StatistiquesPeer-reviewedCC BY 4.0Full textStatisticsHAL
BibTeX
@article{safai2026community,
  title = {{Community Experience of COVID-19 Hospitalizations.}},
  author = {Kourosh Safai and Alexis Case and Amanda Frugoli and Timothy Pisarski and Kaylie Heyer and Graal Diaz},
  journal = {Cureus},
  year = {2026},
  month = sep,
  doi = {10.7759/cureus.116652},
  url = {https://europepmc.org/article/MED/42910043},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Community Experience of COVID-19 Hospitalizations.
AU  - Kourosh Safai
AU  - Alexis Case
AU  - Amanda Frugoli
AU  - Timothy Pisarski
AU  - Kaylie Heyer
AU  - Graal Diaz
PY  - 2026
DA  - 2026/09/21
JO  - Cureus
DO  - 10.7759/cureus.116652
UR  - https://europepmc.org/article/MED/42910043
AB  - Background Every American was affected by the COVID-19 pandemic. The novelty and virulence spurred the rapid evolution of treatment strategies. While large multicenter studies established key mortality risk factors and treatment efficacy, community hospital experiences are underrepresented. Methods This retrospective study examines clinical characteristics, mortality predictors, and outcome trends among 1,949 adults hospitalized with COVID-19 at a Southern California community hospital from January 31, 2020, through May 11, 2023. Results Overall mortality was 7.6%, and the mean length of stay was 9.2 days. Older age was independently associated with increased mortality, with the odds of death nearly doubling for every decade of life (adjusted odds ratio (aOR) 1.98, 95% CI 1.65-2.39, P < 0.001). Univariable laboratory predictors of inpatient mortality, and log transformation of D-dimer, demonstrated that D-dimer was the best predictor of inpatient mortality. Septic shock was associated with a twofold increase in mortality (aOR 2.26, 95% CI 1.11-4.63, P = 0.025). Respiratory failure requiring a mechanical ventilator is a marker for disease severity and was the strongest predictor of mortality in this cohort. Mechanical ventilation was associated with a 10-fold increase in the odds of death (aOR 10.07, 95% CI 6.18-16.38, P < 0.001). Multivariable analysis comparing mortality and pharmaceutical treatments identified that receipt of systemic corticosteroids was associated with higher odds of in-hospital mortality (aOR 6.70; 95% CI 4.00-11.22; P < 0.001). Receipt of tocilizumab was also associated with higher mortality (aOR 3.87; 95% CI 2.06-7.26; P < 0.001). Time-lapse analysis of the interval between admission and mortality demonstrated a 23% reduction in the odds of death per successive year (aOR 0.77 per year, 95% CI 0.62-0.96, P = 0.018). Conclusion Mortality decreased nearly one-fourth each year. D-dimer was the best laboratory predictor of death. Older age, septic shock, and ventilator need were associated with increased risk of inpatient mortality. Receipt of systemic steroids and tocilizumab was associated with higher mortality. These are not causal treatment effects, as medication receipt at that time was related to disease severity. These community hospital findings complement larger studies and reinforce the importance of early risk stratification and evidence-based treatments.
SN  - 2168-8184
ER  -